The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques
Abstract
The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-γ-inducible protein-10 (CXCL10), and MIP-3α (CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-γ, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Old, L. J. (1985) · Science · doi:10.1126/science.2413547 · Cited by 1,895
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationLee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Self-citationEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Self-citationGrossman, R. M., Krueger, J., Yourish, D., Granelli-Piperno, A., Murphy, D. P., May, L. T., Kupper, T. S., Sehgal, P. B., & Gottlieb, A. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6367 · Cited by 853
Self-citationGottlieb, S. L., Gilleaudeau, P., Johnson, R., Estes, L., Woodworth, T. G., Gottlieb, A. B., & Krueger, J. G. (1995) · Nature Medicine · doi:10.1038/nm0595-442 · Cited by 606
Self-citationThe immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Self-citationGottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D., Bala, M., Marano, C. W., & Menter, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.021 · Cited by 581
Self-citation
Cited by
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Self-citationJang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.59 · Cited by 1,129
Sutton, C., Brereton, C., Keogh, B., Mills, K. H. G., & Lavelle, E. C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060285 · Cited by 1,010
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Self-citationChan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060244 · Cited by 680
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071094 · Cited by 676
Self-citationMa, H.-L., Liang, S., Li, J., Napierata, L., Brown, T., Benoit, S., Senices, M., Gill, D., Dunussi-Joannopoulos, K., Collins, M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33263 · Cited by 544
Analyzing proteome topology and function by automated multidimensional fluorescence microscopy
Schubert, W., Bonnekoh, B., Pommer, A. J., Philipsen, L., Böckelmann, R., Malykh, Y., Gollnick, H., Friedenberger, M., Bode, M., & Dress, A. W. M. (2006) · Nature Biotechnology · doi:10.1038/nbt1250 · Cited by 479
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132448 · Cited by 462
Pathogenesis of psoriasis and development of treatment
Ogawa, E., Sato, Y., Minagawa, A., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14139 · Cited by 456
Zaba, L. C., Fuentes-Duculan, J., Eungdamrong, N. J., Abello, M. V., Novitskaya, I., Pierson, K. C., Gonzalez, J., Krueger, J. G., & Lowes, M. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.194 · Cited by 442
Self-citationCarrier, Y., Ma, H.-L., Ramon, H. E., Napierata, L., Small, C., O'Toole, M., Young, D. A., Fouser, L. A., Nickerson-Nutter, C., Collins, M., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.234 · Cited by 425
Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines
Fitch, E., Harper, E., Skorcheva, I., Kurtz, S. E., & Blauvelt, A. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0075-1 · Cited by 415
Schafer, P., Parton, A., Gandhi, A., Capone, L., Adams, M., Wu, L., Bartlett, J., Loveland, M., Gilhar, A., Cheung, Y., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00559.x · Cited by 406
Guilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F.-X., Lecron, J.-C., & Morel, F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902464 · Cited by 353
The Multitasking Organ: Recent Insights into Skin Immune Function
Di Meglio, P., Perera, G. K., & Nestle, F. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.12.003 · Cited by 348
Scanning the Immunopathogenesis of Psoriasis
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., & Romanelli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010179 · Cited by 320
Johnston, A., Xing, X., Guzman, A. M., Riblett, M., Loyd, C. M., Ward, N. L., Wohn, C., Prens, E. P., Wang, F., Maier, L. E., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003162 · Cited by 319
Di Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation
Kikly, K., Liu, L., Na, S., & Sedgwick, J. D. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.008 · Cited by 303
Wang, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27180 · Cited by 276
“Etanercept is well suited for the study of the effect of blocking TNF-a function in the regulation of cellular events during the development of psoriasis, as its action is due to neutralization of soluble TNF-a and not to the depletion of cells with membrane-bound TNF-a (10).”
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
What is a role of haeme oxygenase‐1 in psoriasis? Current concepts of pathogenesis
Wojas‐Pelc, A., & Marcinkiewicz, J. (2007) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2006.00505.x · Cited by 36
Metadata
- Authors
- Gottlieb, A. B., Chamian, F., Masud, S., Cardinale, I., Abello, M. V., Lowes, M. A., Chen, F., Magliocco, M., & Krueger, J. G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08
- Volume
- 175
- Issue
- 4
- Pages
- 2721-2729
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1637051416
- Cited by
- 372
- References
- 51
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.